Critical reading for those interested in Alzheimer's clinical trials: first results from the BAP Phase III program. The link includes additional links to a New York Times article and a company press release.
From FierceBiotech:
UPDATED: Pfizer, J&J Alzheimer's drug bapineuzumab flunks out in big PhIII
July 23, 2012
By John Carroll
Examine media reports this week for these results and accompanying analysis and commentary. Those who have been following this clinical-trial program should examine the corporate press release for additional details about the other three Phase III trials in this program (which were not part of today's results).
Comments